Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Quantitative Translational Analysis of Brain Kynurenic Acid Modulation via Irreversible Kynurenine Aminotransferase II Inhibition.

Chang C, Fonseca KR, Li C, Horner W, Zawadzke LE, Salafia MA, Welch KA, Strick CA, Campbell BM, Gernhardt SS, Rong H, Sawant-Basak A, Liras J, Dounay A, Tuttle JB, Verhoest P, Maurer TS.

Mol Pharmacol. 2018 Aug;94(2):823-833. doi: 10.1124/mol.118.111625. Epub 2018 May 31.

PMID:
29853495
2.

Discovery and Characterization of (R)-6-Neopentyl-2-(pyridin-2-ylmethoxy)-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-one (PF-06462894), an Alkyne-Lacking Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator Profiled in both Rat and Nonhuman Primates.

Stepan AF, Claffey MM, Reese MR, Balan G, Barreiro G, Barricklow J, Bohanon MJ, Boscoe BP, Cappon GD, Chenard LK, Cianfrogna J, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Ghosh S, Hou X, Houle C, Karki K, Lazzaro JT, Mancuso JY, Marcek JM, Miller EL, Moen MA, O'Neil S, Sakurada I, Skaddan M, Parikh V, Smith DL, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Won A, Wright AS, Whritenour J, Zasadny K, Zaleska MM, Zhang L, Shaffer CL.

J Med Chem. 2017 Sep 28;60(18):7764-7780. doi: 10.1021/acs.jmedchem.7b00604. Epub 2017 Sep 13.

PMID:
28817277
3.

Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.

Dounay AB, Tuttle JB, Verhoest PR.

J Med Chem. 2015 Nov 25;58(22):8762-82. doi: 10.1021/acs.jmedchem.5b00461. Epub 2015 Aug 5. Review.

PMID:
26207924
4.

Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.

Zhang L, Balan G, Barreiro G, Boscoe BP, Chenard LK, Cianfrogna J, Claffey MM, Chen L, Coffman KJ, Drozda SE, Dunetz JR, Fonseca KR, Galatsis P, Grimwood S, Lazzaro JT, Mancuso JY, Miller EL, Reese MR, Rogers BN, Sakurada I, Skaddan M, Smith DL, Stepan AF, Trapa P, Tuttle JB, Verhoest PR, Walker DP, Wright AS, Zaleska MM, Zasadny K, Shaffer CL.

J Med Chem. 2014 Feb 13;57(3):861-77. doi: 10.1021/jm401622k. Epub 2014 Jan 22.

PMID:
24392688
5.

PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.

Dounay AB, Anderson M, Bechle BM, Evrard E, Gan X, Kim JY, McAllister LA, Pandit J, Rong S, Salafia MA, Tuttle JB, Zawadzke LE, Verhoest PR.

Bioorg Med Chem Lett. 2013 Apr 1;23(7):1961-6. doi: 10.1016/j.bmcl.2013.02.039. Epub 2013 Feb 15.

PMID:
23466229
6.

Structure-Based Design of Irreversible Human KAT II Inhibitors: Discovery of New Potency-Enhancing Interactions.

Tuttle JB, Anderson M, Bechle BM, Campbell BM, Chang C, Dounay AB, Evrard E, Fonseca KR, Gan X, Ghosh S, Horner W, James LC, Kim JY, McAllister LA, Pandit J, Parikh VD, Rago BJ, Salafia MA, Strick CA, Zawadzke LE, Verhoest PR.

ACS Med Chem Lett. 2012 Oct 24;4(1):37-40. doi: 10.1021/ml300237v. eCollection 2013 Jan 10.

7.

Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.

Verhoest PR, Fonseca KR, Hou X, Proulx-Lafrance C, Corman M, Helal CJ, Claffey MM, Tuttle JB, Coffman KJ, Liu S, Nelson F, Kleiman RJ, Menniti FS, Schmidt CJ, Vanase-Frawley M, Liras S.

J Med Chem. 2012 Nov 8;55(21):9045-54. doi: 10.1021/jm3007799. Epub 2012 Jul 25.

PMID:
22780914
8.

Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia.

Dounay AB, Anderson M, Bechle BM, Campbell BM, Claffey MM, Evdokimov A, Evrard E, Fonseca KR, Gan X, Ghosh S, Hayward MM, Horner W, Kim JY, McAllister LA, Pandit J, Paradis V, Parikh VD, Reese MR, Rong S, Salafia MA, Schuyten K, Strick CA, Tuttle JB, Valentine J, Wang H, Zawadzke LE, Verhoest PR.

ACS Med Chem Lett. 2012 Jan 25;3(3):187-92. doi: 10.1021/ml200204m. eCollection 2012 Mar 8.

9.

A general strategy for the synthesis of cyclic N-aryl hydroxamic acids via partial nitro group reduction.

McAllister LA, Bechle BM, Dounay AB, Evrard E, Gan X, Ghosh S, Kim JY, Parikh VD, Tuttle JB, Verhoest PR.

J Org Chem. 2011 May 6;76(9):3484-97. doi: 10.1021/jo200530j. Epub 2011 Apr 11.

PMID:
21452845
10.

Origin and characterization of retrograde labeled neurons supplying the rat urethra using fiberoptic confocal fluorescent microscopy in vivo and immunohistochemistry.

Lee KC, Sharma S, Tuttle JB, Steers WD.

J Urol. 2010 Oct;184(4):1550-4. doi: 10.1016/j.juro.2010.05.092. Epub 2010 Aug 21.

PMID:
20728104
11.

Nerve growth factor attenuates oxidant-induced β-amyloid neurotoxicity in sporadic Alzheimer's disease cybrids.

Onyango IG, Ahn JY, Tuttle JB, Bennett JP Jr, Swerdlow RH.

J Neurochem. 2010 Sep;114(6):1605-18. doi: 10.1111/j.1471-4159.2010.06871.x. Epub 2010 Jul 30.

12.

New tools to study bladder dysfunction.

Tuttle JB.

J Urol. 2010 Feb;183(2):423-4. doi: 10.1016/j.juro.2009.11.069. Epub 2009 Dec 14. No abstract available.

PMID:
20006857
13.

Fiberoptic imaging for urologic surgery.

Tuttle JB, Steers WD.

Curr Urol Rep. 2009 Jan;10(1):60-4. Review.

PMID:
19116097
14.

Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?

Klausner AP, Sharma S, Fletcher S, Neff P, Yang SK, Son H, Tuttle JB, Steers WD.

J Urol. 2008 Mar;179(3):1173-7. doi: 10.1016/j.juro.2007.10.034.

PMID:
18206173
15.

Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation.

Lysiak JJ, Yang SK, Klausner AP, Son H, Tuttle JB, Steers WD.

J Urol. 2008 Feb;179(2):779-85. Epub 2007 Dec 20.

PMID:
18082193
16.

Fiberoptic imaging of cavernous nerves in vivo.

Boyette LB, Reardon MA, Mirelman AJ, Kirkley TD, Lysiak JJ, Tuttle JB, Steers WD.

J Urol. 2007 Dec;178(6):2694-700. Epub 2007 Oct 22.

PMID:
17945279
17.

Organocatalytic transfer hydrogenation of cyclic enones.

Tuttle JB, Ouellet SG, MacMillan DW.

J Am Chem Soc. 2006 Oct 4;128(39):12662-3.

PMID:
17002356
18.

Increased expression of heat shock protein 20 and decreased contractile stress in obstructed rat bladder.

Batts TW, Klausner AP, Jin Z, Meeks MK, Ripley ML, Yang SK, Tuttle JB, Steers WD, Rembold CM.

J Urol. 2006 Oct;176(4 Pt 1):1679-84.

PMID:
16952713
19.

Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders.

Steers WD, Tuttle JB.

Nat Clin Pract Urol. 2006 Feb;3(2):101-10. Review.

PMID:
16470209
20.

Blockade of angiotensin II and aging: is the spontaneously hypertensive rat a suitable model?

Tuttle JB.

J Hypertens. 2006 Jan;24(1):27. No abstract available.

PMID:
16331094
21.

The role of corticotropin releasing factor and its antagonist, astressin, on micturition in the rat.

Klausner AP, Streng T, Na YG, Raju J, Batts TW, Tuttle JB, Andersson KE, Steers WD.

Auton Neurosci. 2005 Dec 30;123(1-2):26-35. Epub 2005 Oct 26.

PMID:
16256445
26.

Enantioselective organocatalytic hydride reduction.

Ouellet SG, Tuttle JB, MacMillan DW.

J Am Chem Soc. 2005 Jan 12;127(1):32-3.

PMID:
15631434
27.

Alterations in voiding frequency and cystometry in the clomipramine induced model of endogenous depression and reversal with fluoxetine.

Lee KS, Na YG, Dean-McKinney T, Klausner AP, Tuttle JB, Steers WD.

J Urol. 2003 Nov;170(5):2067-71.

PMID:
14532855
28.

Editorial: Spontaneous contractile activity in rat bladder.

Tuttle JB.

J Urol. 2003 Jul;170(1):280. No abstract available.

PMID:
12796705
29.

Methylpyridinium (MPP(+))- and nerve growth factor-induced changes in pro- and anti-apoptotic signaling pathways in SH-SY5Y neuroblastoma cells.

Halvorsen EM, Dennis J, Keeney P, Sturgill TW, Tuttle JB, Bennett JB Jr.

Brain Res. 2002 Oct 11;952(1):98-110.

PMID:
12363409
30.

Histological and neurotrophic changes triggered by varying models of bladder inflammation.

Dupont MC, Spitsbergen JM, Kim KB, Tuttle JB, Steers WD.

J Urol. 2001 Sep;166(3):1111-8.

PMID:
11490308
31.

In vivo and in vitro investigation of the effects of sildenafil on rat cavernous smooth muscle.

Gemalmaz H, Waldeck K, Chapman TN, Tuttle JB, Steers WD, Andersson KE.

J Urol. 2001 Mar;165(3):1010-4.

PMID:
11176531
33.

Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells.

Sherer TB, Trimmer PA, Borland K, Parks JK, Bennett JP Jr, Tuttle JB.

Brain Res. 2001 Feb 9;891(1-2):94-105.

PMID:
11164812
34.
35.

Altered neural control of micturition in the aged F344 rat.

Chai TC, Andersson KE, Tuttle JB, Steers WD.

Urol Res. 2000 Oct;28(5):348-54.

PMID:
11127716
36.
37.

Mitochondrial DNA-depleted neuroblastoma (Rho degrees) cells exhibit altered calcium signaling.

Sherer TB, Trimmer PA, Parks JK, Tuttle JB.

Biochim Biophys Acta. 2000 Apr 17;1496(2-3):341-55.

38.

Calcium homeostasis and nerve growth factor secretion from vascular and bladder smooth muscle cells.

Sherer TB, Clemow DB, Tuttle JB.

Cell Tissue Res. 2000 Feb;299(2):201-11.

PMID:
10741461
39.

Mitochondrial impact on nerve growth factor production in vascular smooth muscle-derived cells.

Sherer TB, Neff PS, Parks JK, Tuttle JB.

Biochim Biophys Acta. 1999 Dec 27;1473(2-3):305-20.

PMID:
10594368
40.

The effect of sildenafil on apomorphine-evoked increases in intracavernous pressure in the awake rat.

Andersson KE, Gemalmaz H, Waldeck K, Chapman TN, Tuttle JB, Steers WD.

J Urol. 1999 May;161(5):1707-12.

PMID:
10210444
41.

Persistently increased voiding frequency despite relief of bladder outlet obstruction.

Chai TC, Gemalmaz H, Andersson KE, Tuttle JB, Steers WD.

J Urol. 1999 May;161(5):1689-93.

PMID:
10210441
42.

Altered NGF regulation may link a genetic predisposition for hypertension with hyperactive voiding.

Clemow DB, Spitsbergen JM, McCarty R, Steers WD, Tuttle JB.

J Urol. 1999 Apr;161(4):1372-7.

PMID:
10081910
43.

The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males.

Steers WD, Clemow DB, Persson K, Sherer TB, Andersson KE, Tuttle JB.

Exp Physiol. 1999 Jan;84(1):137-47. Review.

PMID:
10081714
44.
46.

Arterial nerve growth factor (NGF) mRNA, protein, and vascular smooth muscle cell NGF secretion in hypertensive and hyperactive rats.

Clemow DB, Spitsbergen JM, McCarty R, Steers WD, Tuttle JB.

Exp Cell Res. 1998 Oct 10;244(1):196-205.

PMID:
9770362
47.

Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats.

Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE.

Am J Physiol. 1998 Oct;275(4):R1366-73. doi: 10.1152/ajpregu.1998.275.4.R1366.

PMID:
9756570
48.

Altered regulation of bladder nerve growth factor and neurally mediated hyperactive voiding.

Clemow DB, Steers WD, McCarty R, Tuttle JB.

Am J Physiol. 1998 Oct;275(4):R1279-86. doi: 10.1152/ajpregu.1998.275.4.R1279.

PMID:
9756561
49.

Mitochondria in sporadic amyotrophic lateral sclerosis.

Swerdlow RH, Parks JK, Cassarino DS, Trimmer PA, Miller SW, Maguire DJ, Sheehan JP, Maguire RS, Pattee G, Juel VC, Phillips LH, Tuttle JB, Bennett JP Jr, Davis RE, Parker WD Jr.

Exp Neurol. 1998 Sep;153(1):135-42.

PMID:
9743575
50.

Mechanical stretch increases secretion of parathyroid hormone-related protein by cultured bladder smooth muscle cells.

Steers WD, Broder SR, Persson K, Bruns DE, Ferguson JE 2nd, Bruns ME, Tuttle JB.

J Urol. 1998 Sep;160(3 Pt 1):908-12.

PMID:
9720586

Supplemental Content

Loading ...
Support Center